176 related articles for article (PubMed ID: 16407233)
1. Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure.
Courtney HS; Zhang YM; Frank MW; Rock CO
J Biol Chem; 2006 Mar; 281(9):5515-21. PubMed ID: 16407233
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins.
Rosales C; Gillard BK; Courtney HS; Blanco-Vaca F; Pownall HJ
Biochemistry; 2009 Aug; 48(33):8070-6. PubMed ID: 19618959
[TBL] [Abstract][Full Text] [Related]
3. Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption.
Gillard BK; Courtney HS; Massey JB; Pownall HJ
Biochemistry; 2007 Nov; 46(45):12968-78. PubMed ID: 17941651
[TBL] [Abstract][Full Text] [Related]
4. Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I.
Han M; Gillard BK; Courtney HS; Ward K; Rosales C; Khant H; Ludtke SJ; Pownall HJ
Biochemistry; 2009 Feb; 48(7):1481-7. PubMed ID: 19191587
[TBL] [Abstract][Full Text] [Related]
5. Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.
Clay MA; Cehic DA; Pyle DH; Rye KA; Barter PJ
Biochem J; 1999 Feb; 337 ( Pt 3)(Pt 3):445-51. PubMed ID: 9895287
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo.
Rosales C; Tang D; Gillard BK; Courtney HS; Pownall HJ
Arterioscler Thromb Vasc Biol; 2011 Aug; 31(8):1834-41. PubMed ID: 21597008
[TBL] [Abstract][Full Text] [Related]
7. The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins.
Courtney HS; Pownall HJ
J Biomed Biotechnol; 2010; 2010():956071. PubMed ID: 20671930
[TBL] [Abstract][Full Text] [Related]
8. Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.
Holvoet P; Zhao Z; Deridder E; Dhoest A; Collen D
J Biol Chem; 1996 Aug; 271(32):19395-401. PubMed ID: 8702626
[TBL] [Abstract][Full Text] [Related]
9. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
10. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions.
Hedrick CC; Castellani LW; Wong H; Lusis AJ
J Lipid Res; 2001 Apr; 42(4):563-70. PubMed ID: 11290828
[TBL] [Abstract][Full Text] [Related]
11. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
[TBL] [Abstract][Full Text] [Related]
12. Formation of new HDL particles from lipid-free apolipoprotein A-I.
Clay MA; Barter PJ
J Lipid Res; 1996 Aug; 37(8):1722-32. PubMed ID: 8864956
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism.
Rosales C; Patel N; Gillard BK; Yelamanchili D; Yang Y; Courtney HS; Santos RD; Gotto AM; Pownall HJ
Biochemistry; 2015 Apr; 54(14):2295-302. PubMed ID: 25790332
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein A-II-mediated conformational changes of apolipoprotein A-I in discoidal high density lipoproteins.
Gauthamadasa K; Vaitinadin NS; Dressman JL; Macha S; Homan R; Greis KD; Silva RA
J Biol Chem; 2012 Mar; 287(10):7615-25. PubMed ID: 22235130
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic deletion of platform apolipoproteins on the size distribution of the murine lipoproteome.
Gordon SM; Li H; Zhu X; Tso P; Reardon CA; Shah AS; Lu LJ; Davidson WS
J Proteomics; 2016 Sep; 146():184-94. PubMed ID: 27385375
[TBL] [Abstract][Full Text] [Related]
16. Contrasting in vivo effects of murine and human apolipoprotein A-II. Role of monomer versus dimer.
Gong EL; Stoltfus LJ; Brion CM; Murugesh D; Rubin EM
J Biol Chem; 1996 Mar; 271(11):5984-7. PubMed ID: 8626380
[TBL] [Abstract][Full Text] [Related]
17. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
18. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.
Chroni A; Kan HY; Kypreos KE; Gorshkova IN; Shkodrani A; Zannis VI
Biochemistry; 2004 Aug; 43(32):10442-57. PubMed ID: 15301543
[TBL] [Abstract][Full Text] [Related]
19. Effect in vitro of apolipoprotein A-V on the structure and functions of recombinant high density lipoprotein.
Zhang X; Wang J; Chen B
Biochem Biophys Res Commun; 2010 Oct; 401(3):473-9. PubMed ID: 20869952
[TBL] [Abstract][Full Text] [Related]
20. Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation.
Dhoest A; Zhao Z; De Geest B; Deridder E; Sillen A; Engelborghs Y; Collen D; Holvoet P
J Biol Chem; 1997 Jun; 272(25):15967-72. PubMed ID: 9188498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
